Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508504 | 1.00 | PDPK1 (0.36) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL1438293 | 1.00 | PDPK1 (0.36) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL23012937 | 0.94 | NR1H4 (0.35) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL27673955 | 0.89 | NR1H4 (0.34) | NR1H4GRM4NR1H2SSTR4PLAU | |
| SCHEMBL2857004 | 0.86 | NR1H4 (0.33) | NR1H4GRM4NR1H2SSTR4PLAU | |
| SCHEMBL29733555 | 0.86 | AURKA (0.33) | — | |
| SCHEMBL8233620 | 0.85 | GABRG2 (0.39) | PDPK1NR1H4GRM4SYKSSTR4 | |
| SCHEMBL22277233 | 0.84 | NR1H4 (0.40) | PDPK1NR1H4GRM2 | |
| SCHEMBL17221287 | 0.84 | ROCK1 (0.47) | PDPK1NR1H4NR1H2GRM2 | |
| SCHEMBL29481424 | 0.84 | ROCK1 (0.47) | PDPK1NR1H4NR1H2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4255900-A2 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | PDPK1 3344/4885NR1H4 545/4885GRM4 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.